Stewart B. Jacobson, DVM, DACVP, Joins BASi as Vice President, Pathology, Filling Key Scientific Leadership Position
October 01 2019 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) is pleased to announce the addition of Stewart B.
Jacobson, DVM, DACVP, as Vice President, Pathology, effective
October 1, 2019. Dr. Jacobson fills an important scientific
leadership position within the Company, which continues to invest
in key appointments to the leadership team.
Dr. Jacobson is an accomplished executive, skilled in strategic
leadership, and brings over eighteen years of experience to the
Company. He has held roles of increasing responsibility, leading
teams and supporting nonclinical research in multiple well-known
contract research organizations.
“Stewart joins us with an impeccable reputation in our industry”
said John E. Sagartz, DVM, PhD, DACVP, BASi’s Chief Strategy
Officer. “His appointment allows us to accelerate the growth of our
pathology center of excellence, and represents an important
milestone in our succession planning. Providing high quality
pathology services, integrated with our in vivo services, has
become increasingly important as we grow our vivarium capacity and
continue to support pathology projects originating externally.”
Before joining BASi, Dr. Jacobson led the operations of the
anatomic and clinical pathology sections at Battelle Memorial
Institute. Prior to Battelle, Dr. Jacobson held senior leadership
positions at SNBL USA, CVPath Institute, and Pathology Associates
within Charles River Laboratories. Dr. Jacobson began his pathology
career at Covance Laboratories as a Staff Pathologist.
Dr. Jacobson received a Bachelor of Science degree in
Engineering/Computer Science from the University of Illinois. He
went on to study veterinary medicine at Tufts, where he received
his Doctor of Veterinary Medicine, then completed a Residency in
Veterinary Anatomic Pathology from the University of
Connecticut.
“This is an exciting opportunity, to join a company with such a
strong reputation in comparative and experimental pathology,” said
Dr. Jacobson. “I am confident in our ability to provide thoughtful
and innovative support to our clients’ R&D activities, while
delivering outstanding service. In addition to supporting internal
toxicology projects, our group will continue to provide expert
analysis of discovery pharmacology studies and inform biomarker
efforts important to translational biology. I look forward to the
opportunity to grow and shape a truly unique organization within
our industry.”
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. BASi’s products focus on increasing
efficiency, improving data, and reducing the cost of taking new
drugs to market. Visit www.BASinc.com for more
information about BASi.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, and various market and operating risks
detailed in the company's filings with the U.S. Securities and
Exchange Commission.
FOR MORE
INFORMATION:
Company Contact:Jill C. BlumhoffChief Financial
OfficerPhone: 765.497.8381jblumhoff@BASinc.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Sep 2023 to Sep 2024